CSII - カ―ディオバスキュラ―・システムズ (Cardiovascular Systems Inc.) カ―ディオバスキュラ―・システムズ



symbol CSII
会社名 Cardiovascular Systems Inc (カ―ディオバスキュラ―・システムズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 カーディオバスキュラー・システムズ(Cardiovascular Systems Inc.)は、医療技術会社であり、動脈カルシウムを含む末梢・冠動脈疾患に罹患する患者の治療に従事する。同社は、末梢・冠状動脈の両方の商用アプリケーションに、軌道アテローム切除技術を開発する。末梢動脈疾患(PAD)システムは、膝の上下の脚動脈におけるプラークタイプを治療できるカテーテルベースのプラットフォームである。同社の主力製品には、「Diamondback 360 Peripheral Orbital Atherectomy System」(OAS) (Diamondback 360 Peripheral)、「Stealth 360 OAS」(Stealth 360)、「Diamondback 360 Peripheral」、「Diamondback 360 60cm Peripheral」、「Diamondback 360 Low Profile Peripheral」、「Diamondback 360 1.50 Peripheral」及び「Diamondback 360 2.00 Peripheral」がある。同社の冠状動脈疾患(CAD)製品である「Diamondback 360 Coronary OAS」(Coronary OAS)は、重度石灰化冠状動脈の治療薬として販売される。   カ―ディオバスキュラ―・システムズは、米国の医療機器メ―カ―。血管疾患のためのインタ―ベンション治療システムの開発と商業化に焦点を当てる。末梢動脈疾患の製品、ステルス360パッドシステム、ダイヤ360パッドシステム、およびプレデタ―360パッドシステムは、カテ―テルベ―スのプラットフォ―ムで、脚の石灰化冠状動脈の治療法として使用される。   Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN.
本社所在地 1225 Old Highway 8 Northwest St. Paul MN 55112-6416 USA
代表者氏名 Scott R. Ward スコットR.ワード
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 651-259-1600
設立年月日 2000年
市場名 NASDAQ National Market System
ipoyear 1981年
従業員数 652人
url www.csi360.com
nasdaq_url https://www.nasdaq.com/symbol/csii
EBITDA EBITDA(百万ドル) 5.96400
終値(lastsale) 36.45
時価総額(marketcap) 1265033663.55
時価総額 時価総額(百万ドル) 1262.951
売上高 売上高(百万ドル) 217.04300
企業価値(EV) 企業価値(EV)(百万ドル) 1167.211
当期純利益 当期純利益(百万ドル) 1.71200
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Cardiovascular Systems Inc revenues increased 6% to $217M. Net income totaled $1.7M vs. loss of $1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Stock-based Compensation in R&D decrease of 4% to $967K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to $0.05.



   Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin  2020/05/06 14:44:00 Zacks Investment Research
Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.
   Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates  2020/05/05 22:45:14 Zacks Investment Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 11.11% and -4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Cardiovascular Systems, Inc. to Webcast Fiscal 2020 Third-Quarter Earnings Conference Call Tuesday, May 5  2020/04/21 11:00:00 Business Wire
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) will host a live webcast of its fiscal 2020 third-quarter conference call on Tuesday, May 5, 2020.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Why Is Cardiovascular Systems (CSII) Down 10.8% Since Last Earnings Report?  2020/03/06 16:30:41 Zacks Investment Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2019 Results - Earnings Call Transcript  2019-05-01
Cardiovascular Systems, Inc. (CSII) Q3 2019 Earnings Conference Call May 1, 2019 4:30 PM ET Company Participants Jack Nielsen Vice President, Investor Relations and Corporate Communications Scott Ward Chairman, President and Chief Executive Officer Jeff Points &…
   Stifel neutral on Incyte in premarket analyst action  2019-04-11
CVS Health (NYSE: CVS ) initiated with Market Perform rating and $58 (8% upside) price target at BMO. Share down a fraction premarket. More news on: CVS Health Corporation, Incyte Corporation, PTC Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more …

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 カ―ディオバスキュラ―・システムズ CSII Cardiovascular Systems Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)